Your session is about to expire
← Back to Search
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF) (BETTER CARE-HF Trial)
N/A
Waitlist Available
Led By Amrita Mukhopadhyay, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests two types of electronic reminders to help doctors prescribe the right medications for heart failure patients. The reminders are sent through best practice alerts and automated messages. The goal is to improve patient care by ensuring that doctors follow treatment guidelines.
Eligible Conditions
- Congestive Heart Failure
- Heart Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: In-Basket Message groupExperimental Treatment1 Intervention
Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
Group II: Best Practice Alert groupExperimental Treatment1 Intervention
Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
Group III: Control groupActive Control1 Intervention
Patients who will receive the current standard practice of care (no BPA or in-basket message)
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,413 Previous Clinical Trials
853,539 Total Patients Enrolled
Amrita Mukhopadhyay, MDPrincipal InvestigatorNYU Langone Health